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Abstract
Alloimmunization also known as isoimmunization, during pregnancy is the 
production of IgG antibodies by the mother against the paternally inherited 
antigens (IPA) in the foetus/newborn. The alloimmunization during pregnancy 
leads to various alloimmune disorders, such as, haemolytic disease of the foetus 
and newborn (HDFN), neonatal alloimmune neutropenia (NAN) and foetal 
and neonatal alloimmune thrombocytopenia (FNAIT) due to the production of 
maternal alloantibodies against the red blood cell antigen, neutrophils and plate-
lets cell antigens, respectively. Recent studies suggest that maternal anti-HLA 
class I alloantibodies may also be the cause of FNAIT in addition to antibodies 
against platelet antigens. On the contrary, studies have also suggested that HLA-
C, a classical HLA class I molecule, and HLA-G, a nonclassical HLA molecule, 
play an important role in placentation and modulation of the maternal immune 
system during pregnancy, respectively, and thereby leading to acceptance of the 
semi allogeneic fetus. So far most of the studies have discussed alloimmuniza-
tion in pregnancy relating to Rh antigen. Thus, in this chapter an attempt has 
been made to discuss alloimmunization in pregnancy caused because of maternal 
alloantibody against HLA antigen and its role in immune modulation during 
pregnancy.
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1. Introduction
Mammalian pregnancy with haemochorial placentation is an immunological 
contradiction with suppression of an immune response against the semi allogeneic 
foetus having inherited paternal antigens foreign to mother [1]. The foetus is not 
rejected as it would have, ideally in case of an unmatched organ transplant, wherein 
the immune system forbids the incursion of any genetic material or protein foreign 
to itself [2].
The protective mechanism which leads to acceptance of the semi allogeneic 
foetus includes: (i) Complete separation of maternal and foetal blood circula-
tion. (ii) Low expression of foetal antigens that may stimulate graft rejection. The 
trophoblast cells originating from foetus lack expression of classical HLA class Ia 
and class II antigen except for very low expression of HLA-C antigens. They express 
HLA class Ib antigens which are known to modulate immune responses at the 
feto-maternal interface [3]. (iii) Involvement of both mother and foetus in order to 
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maintain pregnant uterus as an immune privileged site. (iv) Programming of the 
maternal immune response by factors obtained from placental and extra placental 
membrane [4].
Maternal and foetal cells interact in co-ordination to maintain an immune privi-
leged environment at feto-maternal interface; some instances do occur which lead 
to maternal sensitization thereby leading to various disorders in the foetus/neo-
nate. Alloimmunization during pregnancy is the stimulation of maternal immune 
response by the paternal inherited foetal or placental antigens [5].
The recognition of antigens as self and non-self is the essential process by which 
the immune system determines whether or not to develop an immune response. The 
response of the maternal immune system will depend on genetic and acquired fac-
tors related to the foetus and to antigen immunogenicity. Maternal alloimmunization 
occurs when the foetal and the maternal lymph combine due to rupture of placental 
barrier which often happens during delivery, although feto-maternal haemorrhage 
(FMH) may also result early in pregnancy. The instance of FMH has been observed 
in 7, 16, and 29% of mothers during their first, second and third trimesters, respec-
tively [6]. Other maternal factors responsible for maternal sensitization involve 
factors such as Rh incompatibility, major surgical procedure, blood transfusion, 
multiparity, or operative removal of placenta [7].
The major antigens against which the maternal alloimmunization occurs are 
RBC, granulocytes (neutrophils), human platelet antigens and HLA antigens. 
The sensitization against these antigens leads to disorders, such as, haemolytic 
disease of foetus and newborn (HDFN), neonatal alloimmune neutropenia 
(NAN) and foetal and neonatal alloimmune thrombocytopenia (FNAIT), 
respectively.
Till now most of the studies have addressed the maternal alloimmunization 
relating to Rh and platelet antigen, this book chapter aims at exploring the role of 
human leukocyte antigen (HLA) in pregnancy and alloimmunization along with 
other factors.
2. Role of HLA in pregnancy
The human leukocyte antigen (HLA) also known as the major histocompat-
ibility complex (MHC) play a very crucial role in enabling the immune system to 
differentiate between “self” and “non-self-antigen” [8]. It is situated on the short 
arm of human chromosome 6p21.3, and codes for nearly 130 structural genes 
known to function in antigen presentation to immune system thereby modulating 
the immune response. It is categorized into three classes i.e., class I, class II and class 
III [9]. The HLA class I gene is further classified into classical HLA class Ia genes 
(HLA-A, -B, -C) and non-classical HLA class Ib genes (HLA-E, -F, -G) [3]. The 
non-classical HLA class Ib genes show limited polymorphism as compared to those 
of classical HLA class Ia genes [10]. The HLA class II is differentiated into HLA-
DR,-DQ ,-DM and -DP.
The HLA class I molecules are known to interact with CD8+ T cells, natural killer 
cells (NK cells), and class II molecules with CD4+ T cells, respectively [11, 12] to 
elicit an immune response in order to eliminate the foreign or non-self-antigens. In 
contrast the non-classical HLA class Ib molecules interact with natural killer cells 
(NK cells) and other immune cell to develop an immunological tolerogenic effect. 
HLA plays a very important role in transplantation, as it is known to evoke an 
immune response to the transplanted graft, thus are very critical in pregnancy from 
gamete formation to completion of development, as foetus is the most successful 
semi-allograft.
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The non-classical HLA class Ib molecules, primarily HLA-G plays a very 
important role in maintaining maternal tolerance i.e., an immunosuppressive 
state during pregnancy thereby contributing to foetal endurance and growth. 
Consequently inability in maintaining the maternal tolerance to the foetus, 
adversely affects the pregnancy leading to complications such as recurrent spon-
taneous abortion, foetal growth restriction, and preeclampsia [13]. Also HLA-C 
along with KIR (killer-immunoglobulin receptor) has been implicated to play a 
role in placentation. Thus, the role of HLA along with other immune cells may be 
implicated in maintaining pregnancy as well as at time in leading to pregnancy 
complications.
2.1 HLA-G in immune modulation during pregnancy
Among the non-classical HLA class Ib genes HLA-G is the most studied 
because of its role in immune modulation during pregnancy and its association 
with complexities like pre-eclampsia and recurrent spontaneous abortion in 
pregnancy [14].
2.1.1 Structure and expression of HLA-G
The non-classical class Ib HLA-G gene is situated near to the classical class Ia 
HLA-A gene on chromosome 6 and is also greatly homologous to it. The HLA-G 
gene comprises of seven intronic regions and eight exonic regions. The exon 1 codes 
for the signal peptide. The exons 2–4 code for the external part of HLA-G molecule 
which consist of three parts viz. α1, α2 and α3 domains, exon 5 encodes for the 
transmembrane region, where as exon 6 and a very short part of exon 8 encode for 
the cytoplasmic tail of the HLA-G molecule. The HLA-G gene is translated into a 
38 kDa protein having similar structure as that of HLA class I antigens. It consists 
of a heavy chain that binds a light chain β2-microglobulin a protein coded by a gene 
on chromosome 15. The α1 and α2 extracellular domain of heavy chain form the 
peptide binding groove [15].
The HLA-G antigen has seven splice variants (HLA-G1-HLA-G7) as a result 
of alternative splicing event of the mRNA from the single HLA-G gene, of which 
HLA-G1 is the full length variant and the rest are formed by out-splicing of 
exons. Out of the seven isoform HLA-G1, HLA-G2, HLA- G3 and HLA-G4 are 
membrane-bound and the remaining three i.e., sHLA-G5, sHLA-G6 and sHLA-G7 
are soluble isoforms [16]. The coding region of HLA-G gene shows meagre poly-
morphism but the polymorphisms that are present are equally shared by introns 
and exon 2, 3 and 4. Most of these polymorphism do not modify the protein 
sequence and those which do modify the protein sequence permit to be grouped 
in major allele groups like G*01::xx, G*01:02, G*01:03: xx, G*01:04: xx, G*01:05 N 
(null allele), G*01:06, and G*01:07 to G*01:18. Overall there are 61 alleles and 19 
protein groups representing an amino acid substitution have been delineated in 
the HLA-G gene sequence [WHO Nomenclature Committee for factors of the 
HLA System and the International Immunogenetics Information System (IMGT)/
HLA Database] [15].
HLA-G expression was first reported on human non-villous cytotrophoblast 
cells [17]. Its expression is stringently confined to certain cells, being largely 
expressed in extravillous cytotrophoblast cells. HLA-G5 a soluble variant is present 
throughout the placenta, within the chorion membrane, maternal blood and the 
decidua [18]. Apart from placental expression soluble HLA-G proteins are pres-
ent in peripheral blood of pregnant women, non-pregnant women and men. The 
presence of sHLA-G in the blood of non-pregnant women indicates that it may play 
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an important role in reproduction even before conception. Soluble HLA-G is also 
found in follicular fluid, fertilized oocyte and in male reproductive tissue including 
semen [14]. HLA-G presence can also be detected in tissues like thymic medulla, 
cornea, pancreas and in human mononuclear phagocytic cells [53]. Its expression 
can be stimulated in condition following transplant, viral infections, autoimmune 
diseases and tumors [19].
2.1.2 HLA-G polymorphism
Both coding and non-coding regions of HLA-G gene display polymorphism. 
Exonic polymorphism may affect biological function such as binding of peptides 
or production of isoforms; whereas intronic polymorphism may influence the 
expression of the gene. Codon 31, 35, 57 and 69 of Exon 2 and codon 93, 107 and 110 
of exon 3 coding region display majority of the polymorphism. A large number of 
SNPs (single nucleotide polymorphism) have been found in the non-coding region, 
including the promoter region at 5′UTR (untranslated region) and the 3′UTR. Some 
of these polymorphisms located near the regulatory element have an impact on the 
binding of the corresponding factors.
A 14 bp deletion/insertion have also been reported in the 3′UTR region of exon 
8. These 14 bp del/ins are suspected to affect the size and stability of the mRNA 
transcripts. It was noticed by Rousseau et al. that a 14 bp insertion of sequence 
(5′-ATTTGTTCATGCCT-3′) lead to deletion of 92 bp sequence in the 3′UTR 
region, thereby resulting in production of more stable transcript. Few polymor-
phisms that may also effect the stability of mRNA transcripts, including the SNPs 
located at the position +3142 (C/G) and at +3172 position (G/A) in the 3′UTR 
region [19].
2.1.3 Immune modulation by HLA-G during pregnancy
Approximately 40% of the decidual tissue comprise of maternal immune cells at 
the beginning of pregnancy. Majority of these immune cells are natural killer (CD56 
bright 16−) cells which are distinct from the NK cells (CD56 dim16+) present in the 
peripheral blood as the decidual NK cells have reduced cytotoxic activity. Also the 
decidual NK cells have a higher expression for genes encoding for integrins, lectin-
like receptors, KIR (killer-immunoglobulin like receptors) and cytokines. Along 
with the presence of NK cell decidual tissue also show the presences of macro-
phages, T lymphocytes and dendritic cell [19, 20].
The trophoblast cells of the embryo express HLA-G antigen since the beginning 
of the first trimester and are present till the end of pregnancy. The interaction of 
HLA-G protein at the feto-maternal interface with the immune cell of the decidua 
ensures the foetal tolerance by inhibition of cytotoxic activity of NK cells and CD8+ 
T cells, suppressing the proliferation of alloreactive CD4+ T cells, suppressing the B 
cell activity, leading to the secretion of Th2 cytokines and stimulation of regulatory 
T cells (Treg) [19].
HLA-G intercedes its immunosuppressive activity by interaction of alpha 1 
domain with inhibitory receptors expressed on immune cells. Leukocytes express 
inhibitory receptors like immunoglobulin-like transcripts (ILT)-2, ILT-4 and 
KIR. CD4+ and CD8+ T cells, B cells, monocytes, macrophages and myeloid 
dendritic cells (DC) display ILT-2, interact with only heterodimers of HLA-G1 or 
sHLA-G5 and ß2m. ILT-4 displayed by monocytes, macrophages and myeloid DC’s 
have the capability to also interact with monomers of HLA-G whereas the NK cells 
interact through the KIR2DL4 expressed by them [19] (Figure 1). The interaction 
of these immune cells like decidual NK cells, CD4+ and CD8+ T cells which are 
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HLA-G negative cells with trophoblast cell expressing HLA-G molecule leads to 
the acquisition of HLA-G molecule by immune cells thereby making them HLA-
G+ cells through a process called as trogocytosis. Trogocytosis is a mechanism by 
which surface molecules may be transferred from one cell to another via cell to cell 
contact. The acquisition of the HLA-G molecule by these immune cells contributes 
to an immune suppressive milieu without them expressing HLA-G molecule, but 
only temporarily displaying it [21]. The acquiring of the HLA-G molecule by the 
decidual NK cells is preceded by a cycle of internalization, degradation and reacqui-
sition of HLA-G. This cycle helps NK cells to maintain both tolerance and immune 
function [20].
Figure 1. 
HLA-G molecules expressed by the trophoblast cells interact with the inhibitory receptor KIR2DL4 expressed 
by the NK cells, ILT-2 (Ig-like transcript 2) expressed by NK cells, CD4+ and CD8+ T-cells and B-cells, and 
ILT-2 and ILT-4 expressed by macrophages and dendritic cells. The interaction of the HLA-G with its cognate 
receptors leads to immune tolerogenic effect thereby leading to the acceptance of the foetus by the maternal 
immune system.
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2.1.4 HLA-G and pregnancy disorders
Abnormal placentation and immunological interaction at the feto-maternal 
interface are believed to play very crucial role in placenta-mediated complication of 
late pregnancy (viz. pre-eclampsia, foetal growth restriction, still birth and placen-
tal abruption) and foetal rejection in some pathological pregnancy, respectively. 
Deficient level of HLA-G expression and polymorphisms at HLA-G loci are known 
to be correlated to pregnancy complication especially pre-eclampsia and recurrent 
miscarriages (RM).
Pre-eclampsia is a pregnancy disorder which is clinically evident in the late 
second and third trimester of pregnancy [19]. It is characterised by high blood 
pressure, proteinuria and oedema associated with organ damage and prematurity. 
It is known to be a major cause of perinatal deaths, premature births and intra-
uterine growth restriction with an occurrence of 5–10% of all the pregnancy [22]. 
Though the major cause is unknown, various studies suggest that it may be related 
to maladapted immune system, with low levels of immune regulatory cell and low 
expression of HLA-G molecules [23]. The development of pregnancy has been 
strongly associated with level of soluble HLA-G molecules in the maternal blood. 
Maternal serum with higher levels of sHLA-G has been identified in females with 
successful pregnancy when compared with pre-eclampsia patients [24]. Lower 
sHLA-G levels in the maternal blood, with down regulated HLA-G and decreased 
proportion of HLA-G+ cells have been identified in patients with preeclampsia 
and are thought to be are strongly associated with preeclampsia [24–26]. The 
14 bp ins/del in the 3′UTR of region exon 8 have been extensively studied, and it 
has been reported to be related to severe pre-eclampsia [15]. But on the contrary, 
there are studies which have reported no significant association of the 14 bp 
polymorphism with preeclampsia [24–26] implicating that differences in the 
ethnic population should be considered for the association between HLA-G 14 bp 
polymorphism and serum sHLA-G level. The SNP at position +3172 (G/A) leading 
to decreased in mRNA stability has been linked to pre-eclampsia [19]. Steinborn 
et al. reported that women with soluble HLA-G levels lower than 9.95 ng/ml have 
a risk of 7.1 for developing placental abruption during pregnancy as compared to 
healthy women [3].
Recurrent spontaneous abortion (RSA) is defined as the loss of two or more 
consecutive pregnancy with the same partner [27]. The major causes of RSA are 
considered to be chromosomal abnormalities, anatomical anomalies and endocrine 
disorders along with immunologic dysfunction [28]. Many studies have reported 
increased occurrence of HLA-G allele homozygous for 14 bp ins in women with RSA 
[19]. Also, a study has reported that decreased expression of HLA-G suppresses the 
function of decidual NK cells and thereby may lead to RSA [28]. SNPs−1573T>C 
and −1746C>A in the promoter region of HLA-G gene are shown to be associated 
with RSA [29]. As the level of sHLA-G is known to be associated with the preg-
nancy complication, the measurement of sHLA-G protein may be useful in primary 
diagnosis for the pathogenesis of pregnancy complications.
2.2 Role of HLA-C and KIR during pregnancy
Health of a foetus during pregnancy depends on the supply of nutrients and 
oxygen to the placenta. During placentation the foetal trophoblast cells infiltrate 
into the uterine wall, transforming the spiral artery (maternal artery supplying 
blood to the placenta) into a high-conductance vessel, thereby increasing the 
blood flow to about 100 folds [30]. This transformation allows adequate time for 
gas exchange and also provides sufficient nourishment to the foetus. Defective 
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infiltration of the trophoblast cells into the uterus leads to failure in arterial conver-
sion, thereby leading the arterial blood to squirt into the intervillous space from the 
non-transformed arteries causing impairment of the villous tree (placentation). 
The impaired placentation leads to reduced transport of oxygen and starving of the 
foetus. The clinical manifestation of this failure may result in disorders such foetal 
growth restriction (FGR), preeclampsia, recurrent miscarriage (RM), unexplained 
still birth, placental abruption and preterm labour [31, 32].
The uterus shows abundance of decidual natural killer cells (NK cells) and 
thus, is thought to be involved in placentation and thereby in foetal development. 
Placenta is the site at which maternal allorecognition of the foetus takes place, 
wherein the foetal extra villous trophoblast cells (EVTs) encroach and unify with 
the maternal immune cells. Interaction of maternal KIR present on the uterine NK 
cells and its corresponding ligand, HLA-C which is the only classical HLA class I 
antigen expressed on the trophoblast cells of the foetus are claimed to regulate the 
process of placentation.
There are approximately 14 different KIR genes existing in a linear array in the 
leukocyte receptor complex (LRC) on chromosome 19q13.4. KIRs are differentiated 
on the basis of number of extracellular Ig-like domain (2 or 3) and cytoplasmic tail 
(long or short). They are known to regulate the activity of NK cells, either confer-
ring them with an inhibitory or activating signal. Interaction of KIR with a long 
cytoplasmic tail (e.g., KIR2DL1) with its corresponding ligands leads to generation 
of an inhibitory signal, where as those having a short tail (e.g., KIR2DS1) results in 
activation of NK cells.
The activating and inhibitory genes are differentiated into two haplotype A and 
B. The KIR A haplotype is the most frequently occurring haplotype and consists of 
six inhibitory genes. The KIR B haplotype consist of gene which are more variable 
in their genetic content and are mostly activating KIR. Hence an individual’s KIR 
genotype can be designated as “AA”, “AB”, and “BB”.
The most important ligand for KIR is the HLA-C molecules, and there are 
approximately 4000 alleles of HLA-C. The HLA-C are differentiated into two 
distinct group by KIR, i.e., HLA-C1 and HLA-C2 [33]. HLA-C molecules with 
amino acid asparagine (Asn) at position 80 belong to HLA-C1 group, where as those 
with amino acid lysine (Lys) at the 80th position belong to group C2 of HLA-
C. KIR2DL2/3 (inhibitory receptor) interacts with HLA-C1 allotype and KIR2DL1 
and KIR2DS1 act as receptors for HLA-C present in C2 group [34].
Existence of KIR B haplotype in mother confers protection from pregnancy 
complications, where as its absence may increase the risk of complications [35]. The 
KIR B haplotype consist of activating KIR2DS1 receptor, which on interacting with 
its cognate ligand induces the NK cells to secrete granulocyte-macrophage colony 
stimulating factors and other chemokines known to promote placental trophoblast 
invasion. It also consists of KIR2DL1*004 which is the most common inhibitory 
KIR2DL1 allele on the B haplotype, and is known to have a weak interaction with 
HLA-C2 allotype as compared to alleles present on KIR A haplotype [36]. On the 
contrary, mothers homozygous for KIR A haplotypes (KIR “AA” genotype), with 
foetus having an additional C2 copy as compared to mother (i.e., mother C1/C2 
with foetus C1/C2 or mother C1/C2 with foetus C2/C2), that to when the extra copy 
is of paternal origin are at an increased risk of having a complicated pregnancy [6]. 
As mothers with KIR AA haplotype have two copies of inherited inhibitory KIR for 
HLA-C2 allotype i.e., KIR2DL1, thus when the mothers uterine NK cells possessing 
KIR AA genotype interact with foetal trophoblast cells expressing HLA-C2 allotype, 
it induces a strong inhibitory effect on NK cell which is one of the reasons for 
defective placentation and in turn for various pregnancy related complications [37] 
(Figure 2).
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2.3 Clinical impact of H-Y alloimmunity in secondary recurrent miscarriages 
(SRM)
H-Y antigens are a class of minor histocompatibility antigens (mHAs), encoded 
on Y-chromosome are omnipresent in male cells including foetal and trophoblast 
cells. H-Y antigens exhibit a large amount of similarity to H-X antigen encoded on 
the X-chromosome, but they possess few distinct regions which make them highly 
immunogenic in nature. The H-Y alloimmunity has turned out to be, one of the 
potential reasons for SRM during pregnancy.
SRM is defined as three or more consecutive miscarriages following a successful 
pregnancy as compared to primary recurrent miscarriage (PRM), which is charac-
terized by three or more miscarriages without a previous successful birth. PRM is 
supposed to be caused because of chromosomal defect along with improper implan-
tation of the embryo, whereas SRM are more probably caused due to immunological 
responses [38].
Generally, during pregnancy the cellular and humoral anti-HY immune 
response is well tolerated by the foetus, but in minority of cases the H-Y alloim-
mune response may lead to complications during early or late pregnancy. It has 
Figure 2. 
Model for maternal KIR/foetal HLA-C interaction at the placentation site. The figure depicts foetus 
homozygous for HLA-C2 group with one paternally inherited HLA-C2 molecule. If the mother possesses 
KIR AA genotype, then the inhibitory KIR2DL1 receptor will interact with HLA-C2 molecule expressed by 
trophoblast cells leading to strong inhibition of uterine NK cells thereby resulting in defective placentation. On 
the contrary if the mother possess KIR AB or BB genotype, the activating KIR2DS1 receptor present in the KIR 
B haplotype interacts with HLA-C2 molecule expressed by trophoblast cells stimulating the of uterine NK to 
produce cytokines such as GM-CSF thereby resulting in normal placentation.
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been implicated that pregnancy with a male foetus results in the development of 
alloimmune response towards the H-Y antigen by mother’s immune system, thereby 
predisposing the mother to SRM and also impacting the prospect of subsequent 
pregnancy negatively in terms of perinatal complications and live birth [38, 39].
The presence of H-Y restricted HLA alleles along with H-Y antibodies, have 
also been related to the development of SRM and other pregnancy complications 
[38, 40]. The term “H-Y restricting HLA” is utilized to describe HLA alleles docu-
mented till date, which functionally exhibit H-Y peptides. H-Y restricting HLA 
alleles include the following HLA class I alleles: HLA-A*01, HLAA*02, HLA-B*07, 
HLA-B*08, HLA-B*52, HLA-B*60 and HLA class II alleles: HLA-DRB1*15, -DQB1* 
0501/2, -DRB3*03.
Possessing a HY restricting HLA class II alleles substantially decreases the 
prospect of live birth in patients with SRM and firstborn boys as compared to those 
with firstborn girl. It is implicated that the prospect of live birth decreases in a dose-
response fashion with increasing number of maternal HY-restricting HLA class II 
alleles in patients with firstborn boys [40]. Maternal possession of HY restricting 
HLA class II alleles also reduces the long-term chance of live birth in females with 
SRM [41]. Whereas a mother homozygous for HLA-G 14 bps ins and carrying HY 
restricting class II alleles are predisposed to SRM with the first born boy and also 
negatively affect the birth weight of the boy [42].
In a study, antibodies against both HLA and H-Y antigens during early preg-
nancy were significantly higher in SRM females as compared to females with 
normal pregnancy. The prevalence of these antibodies were associated to low 
subsequent live birth rate whereas the existence of anti H-Y antibodies were related 
to low male/female ratio in subsequent live births [40]. The male: female ratio for 
SRM was observed to be 1.49 prior to miscarriages and 0.76 subsequent to miscar-
riages in a 20 years cohort study [38]. Thus, implicating H-Y antibodies in prevent-
ing implantation or successful gestation of male foetus. Considering H-Y antibodies 
as one of the factors responsible for SRM, IVIG (intravenous immunoglobulin) 
infusions are commonly used as treatment to neutralize the circulating antibodies, 
and it has been shown to improve the birth rates in patients with SRM [38].
3. Rh alloimmunization
The rhesus (Rh) blood group system comprises of more than 50 independent 
antigens and is highly polymorphic of the human blood group [43]. Following ABO, 
Rh blood grouping system is clinically important in transfusion medicine. The 
common Rh antigens are D, C or c, and E or e. Of which the D-antigen is greatly 
immunogenic and stimulates an immune response in 80% of person negative 
for D-antigen, when transfused with a D-antigen positive blood [44, 45]. Thus, 
D-antigen typing is routinely performed on every blood donor and transfusion 
recipient in order to avoid clinical complications due to mismatched transfusions. 
On the contrary, even with the use of anti-D immunoglobulin prophylaxis, there is 
still occurrence of D-alloimmunization in pregnancy.
D-alloimmunization (Rh alloimmunization) in pregnancy occurs due to incom-
patibility of D-antigen between the mother and the foetus. Generally, an individual 
is categorized as Rh-positive if they show an expression of Rh D-antigen on the 
erythrocytes, and Rh negative if there is no expression of D-antigen on the eryth-
rocyte surface [46]. The Rh alloimmunization becomes clinically substantial when 
an Rh negative mother carries a foetus which is Rh-positive. The incompatibility of 
Rh antigen leads to sensitization of mother to the D-antigen, and also to the produc-
tion of anti-D antibodies, which can adhere to and possibly lead to destruction of 
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Rh-positive erythrocytes of foetus. Nevertheless, the Rh incompatibility typically 
does not have an adverse consequence on the initial pregnancy as the foetus is 
delivered prior to the development of anti-D alloimmune response [47]. Although, 
it may also occur during the initial pregnancy due to spontaneous antenatal mixing 
of the foetal and maternal blood. In some instances such as miscarriage, abortion, 
trauma, childbirth and invasive prenatal diagnosis viz. chorionic villous sampling, 
amniocentesis, and pregnancy related uterine curettage may lead to feto-maternal 
haemorrhage thereby causing maternal exposure to foetal blood and consequently 
leading to alloimmunization [48]. The risk of Rh D immunization is estimated 
to be 1.5–2% in sensitized women following spontaneous miscarriage and 4–5% 
after dilation and curettage [49, 50]. Once the mother has been alloimmunized, 
subsequent pregnancies are at an increased risk, for the development of haemolytic 
disease of the new born (HDN) if the foetus is incompatible i.e., Rh-positive [45]. 
The diagnostic and clinical management of HDN is described in Section 4.1.
4. Disease caused due to alloimmunization in pregnancy
4.1 Haemolytic disease of foetus/newborn (HDFN)
Alloantibodies against the Rh antigen are the most common reason for intensive 
haemolytic disease in the neonates. Although the rate at which clinically signifi-
cant HDFN occurs is relatively low viz. 3/100,000–80/100,000 live births [51]. 
In comparison to Rh antigen, alloantibodies to Kell (K and k), Duffy (Fya), Kidd 
(Jka and Jkb), and MNSs (M, N, S, and s) antigens, are also known to lead severe 
haemolytic disease in the foetus [52]. Although over 50 different non-ABO red 
cell surface antigens are thought to be involved in leading to HDFN, but the most 
relevant and significant alloantibodies causing HDFN are anti-RhD [44], anti-Rhc, 
and anti-Kell (K1) [53]. HDN due to Kell alloimmunization results in haemolysis 
and direct inhibition of erythropoiesis by Kell antibodies, as the Kell antigen is 
expressed on the surface of erythroid progenitor [6, 54]. Alloimmunization due to 
anti-Kell antibodies results in critical foetal disease even at lower maternal antibody 
titre than in Rhesus disease [6]. ABO incompatibility also causes HDN, but it occurs 
exclusively in mother with type-O blood with foetus having type-A or type-B blood. 
1% of the type-O mothers possess a high titre of IgG antibodies against both A and 
B antigens. They cross the placental barrier and lead to haemolysis. Mothers with 
type-A or type-B antigen have the occurrence of IgM antibodies which are incapable 
of crossing the placental barrier thus have no role in alloimmunization during 
pregnancy [6].
A neonate delivered by an alloimmunized mother displays clinical indica-
tion based on the severity of the disease. General indications are jaundice, pallor, 
hepatosplenomegaly, and foetal hydrops in severe cases. Neonates with HDN very 
frequently suffer anaemia due to destruction of RBCs by reticuloendothelial system 
and in some due to intravascular destruction. Rarely conjugated hyperbilirubine-
mia is suffered by the neonate due to placental or hepatic dysfunction with severe 
haemolytic disease.
Foetal anaemia can be diagnosed using ultrasound, cardiotocography and 
cordocentesis [48]. High resolution ultrasonography has supported in early diag-
nosis of early hydrops and has also lowered the foetal trauma and fatality rate 
to approximately 2% while performing percutaneous umbilical blood sampling 
(PUBS) and placental trauma during amniocentesis. Rh and ABO alloimmunization 
can be diagnosed using indirect Coombs test and direct antibody test [6]. Currently 
in order to prevent alloimmunization in mothers having maternal and foetal Rh 
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incompatibility Rh immunoglobulin (RhIG) is administered at the 28th week of 
pregnancy. This has critically helped in reducing the instances of HDFN due to 
anti-D alloantibody [6, 55]. Postnatal HDFN treatment consists of intensive photo-
therapy and exchange transfusions to treat severe hyperbilirubinemia and top-up 
transfusions to treat early and late anaemia [56].
4.2 Foetal/neonatal alloimmune thrombocytopenia (FNAIT)
Maternal alloantibodies against foetal human platelet antigens (HPA) cause 
FNAIT. It is comparatively an infrequent condition occurring in 1–800/2000 live 
new born. The alloantibodies are IgG antibodies against the paternal HPA antigens 
and are responsible for destruction of platelets in the foetus or the newborn. Almost 
80% of the instances of FNAIT are a consequence of maternal and foetal incompat-
ibility to HPA-1a, the rest 20% results from incompatibility to HPA-5b on GPIa and 
other HPAs [57]. In addition to HPA antigens, antibodies against CD36 glycoprotein 
a member of class B scavenger receptor family [58] is also implicated in the causal of 
FNAIT. A case study reported, maternal deficiency in expression of CD36 protein 
lead to maternal immunization against CD36 protein (anti-NAK) [59]. The clinical 
impact of NAIT is related with maternal immunization against CD36 is analogous to 
that observed in infants affected by HPA specific antibodies [60].
Alloantibody production by maternal immune system requires the presentation 
of antigen to maternal T-cell through HLA class II molecules. It was reported that 
HPA-1a alloimmunization is mediated by interaction of HPA-1a peptides to HLA 
DRB3*01:01 molecule [57, 61]. This may be a consequence of feto-maternal haemor-
rhage, which can happen during delivery or abortion, as a consequence of platelet 
leakage into maternal circulation [62]. Maternal IgG alloantibody thus formed is 
progressively transported to the foetus through the neonatal Fc receptor, whereas 
the IgA and IgM are not transported as there are no specific receptors for them. 
Once through the placenta, the maternal alloantibody opsonises the foetal platelets 
thereby resulting in their destruction and leading to thrombocytopenia [62–64].
The clinical indication of FNAIT differs from asymptomatic thrombocytopenia 
to life threatening intracranial haemorrhage (ICH) [57]. Intraparenchymal haemor-
rhage in the temporal lobe is also most often noticed in FNAIT [65]. Studies have 
also shown that antibodies against HPA-1a antigen or thrombocytopenia may also 
result in decreased birth weight and a very low weight for gestational age which 
presents a health risk later in life [66]. In many of the FNAIT instance, the illness 
presents as, petechiae, hematomas, haemoptysis, retinal bleeding and haematuria 
[57, 67]. Occasionally, the bleeding due to FNAIT is diagnosed during foetal life in 
ultrasound abnormalities [68]. Without routine screening for HPA antibodies the 
disease is mostly detected after the delivery of the first affected child. Thus, mak-
ing antenatal treatment and diagnosis possible only for subsequent pregnancies in 
order to prevent recurrence of severe FNAIT [69]. FNAIT may be diagnosed using 
antibody detection methods using serological or ELISA based techniques or by 
platelet typing using PCR-based assays.
The immediate treatment for thrombocytopenia in case of severe bleeding 
is platelet transfusion [68, 70]. In addition to transfusion intravenous immuno-
globulin IVIG can be provided to prolong the survival of incompatible platelets 
and reduce the overall impact of thrombocytopenia [71, 72]. The most favourable 
antenatal treatment in order to prevent bleeding complications in pregnancies with 
FNAIT is non-invasive IVIG treatment on weekly basis [68]. In FNAIT resulting 
due to anti-CD36 glycoprotein intrauterine transfusions with compatible RBC and 
CD36 null platelets are useful in preventing the hazardous clinical effect of the 
disease [73].
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4.3 Neonatal alloimmune neutropenia (NAN)
Neonatal alloimmune neutropenia (NAN) is a very rare disorder, but is a life 
threatening disorder of the neonates. The occurrence of NAN has been estimated to 
be 1 in 1000/6000 live births. NAN occurs due to maternal sensitization to incom-
patible paternal foetal granulocyte antigens. The maternal alloantibodies formed 
against the foetal granulocytes are transported through the placenta which thereby 
causes the destruction of foetal granulocytes [74].
Maternal alloantibodies against granulocyte-specific antigens HNA-1a and 
HNA-1b have been accounted widely to cause NAN. Antibodies to Fc gamma RIIb 
(CD16) and HNA-2a granulocyte antigen are infrequently involved in neonatal neu-
tropenia, if mother is HNA-1 null phenotype [74, 75]. A case study has also reported 
the involvement of HNA-4b as a causative of severe NAN [76].
Neutropenia in neonates is a self-limiting disorder and lasts for only few weeks, 
but in some instances, it can prevail for as long as 6 months. In the course of this 
period, neonates are at severe risk of acquiring infection [75]. Symptomatic neonate 
suffering NAN frequently present with retarded umbilical cord separation, skin 
infections, otitis media, or pneumonia within 15 days of life. Most of the infec-
tions that occur are mild, but it may at times turn severe. The fatality rate because 
of NAN has been noted to be around 5%. The severity of NAN is dependent on 
concentration and the subclass of IgG present [74].
The immune neutropenia correlates with granulocytes specific antibodies 
present in the serum and can be diagnosed [75] using the granulocyte agglutina-
tion test (GAT), the granulocyte immunofluorescence test (GIFT), the monoclonal 
antibody immobilization of granulocyte antigens assay (MAIGA), an assay called as 
extracted granulocyte immunofluorescence assay (EGIFA) measures the anti-HNA-
1a, -1b, and/or -2 antibodies in the sera. The use of EGIFA assay has been reported 
to improve the diagnosis and clinical management of patient suspected to have NAN 
[77]. The treatment for NAN is still a matter of discussion, but the options used for 
the management of NAN include antibiotics, intravenous immunoglobulin (IVIG), 
corticosteroids, and human granulocyte colony-stimulating factor (rhG-CSF) [78].
5. Conclusions
Table 1 summarizes the implication of HLA antigens in complications related 
to pregnancy. Though it is now well identified that the HLA plays major role in 
pregnancy, placentation and immune modulation to maintain an immune-tolerance 
Disease/disorder Associated HLA allele/
class
Study findings/outcomes Reference
Rh isoimmunization HLA A3, B17, CW2 and 
DR4.
Inheritance of HLA HLA A3, 
B17, Cw2 and DR4 increased 
the risk of Rh immunization.
Kumar et al. 
[79]
NAIT HLA-DRB3*0101. Presence of HLA-DRB3*0101 
restricted CD4+ cells 
specific for HPA-1a 
antigen in alloimmunized 
women. Implicates strong 
association of DRB3*0101 in 
immunization of pregnant 
women against foetal HPA-1a 
antigen.
Ahlen et al. 
[61]
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state. This in turn results in foetus being well accepted by the maternal immune 
system. Alloimmunization and other pregnancy complications result due to mal-
adapted immune system when the maternal immune system is unable to maintain 
an immune tolerance state towards the foetus.
Disease/disorder Associated HLA allele/
class
Study findings/outcomes Reference
Reduced birth weight 
of foetus with NAIT
Maternal anti-HLA class I 
antibodies.
Increased level of maternal 
anti-HLA class I antibodies in 
thrombocytopenic neonates 
are associated with reduce 
foetal growth.
Dahl et al. 
[80]
Reproductive 
failure (recurrent 
miscarriages and 
pre-eclampsia)
Group 2 HLA-C alleles 
(C2).
Foetus expresses both 
maternally and paternally 
inherited HLA-C antigens. 
Substantial increase in 
the risk for reproductive 
disorders with mother 
possessing KIR “AA” 
genotype and foetus 
expressing more C2 copies 
than mother.
Hiby et al. [35]
Recurrent 
spontaneous abortion
HLA-G with 14 bp 
polymorphism and SNP 
3127(C/G) in the 3′UTR.
Substantial increased 
frequencies of the genotypes 
with 14 bp polymorphism 
and the SNP3127 (C/G) in 
the 3′UTR in RSA women of 
Caucasian origin.
Larsen et al. 
[81]
Recurrent pregnancy 
loss (RPL)
−1573T > C and 
−1746C > A SNPs in the 
promoter of the HLA-G 
gene HLA-G promoter 
region haplotype 
H1(ATCCAGGTAC 
GCAA) 
H2(CTTCGAGAAC 
GCAG).
SNP −1573T > C and 
−1746C > A in the promoter 
region of HLA-G gene are 
associated with RPL H1 is 
associated with a decreased 
and H2 is associated with an 
increased risk of RPL.
Yazdani et al. 
[29]
Pre-eclampsia HLA-G with 14 bp 
polymorphism.
Increased frequencies of 
the +14 insertion/deletion 
HLA-G genotype of 
offspring were associated 
with severe and early onset 
of pre-eclampsia in Chinese 
population.
Zhang et al. 
[82]
Secondary recurrent 
miscarriage
HY (male specific minor 
histocompatibility 
antigen).
Aberrant maternal immune 
response against foetal 
HY antigen play a role 
in secondary recurrent 
miscarriage and other 
pregnancy complications.
Christiansen 
et al. [40]
Still birth HY-restricting HLA class 
II alleles.
Maternal carriage of 
HY-restricting HLA class II 
alleles decreases long-term 
chance of live birth in women 
with RPL after a boy.
Kolte et al. 
[41]
Table 1. 
Role of HLA in pregnancy disease/disorders.
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